Publication | Open Access
A phase I study of intermittent infusion cladribine in patients with solid tumors
15
Citations
23
References
1994
Year
At the MTD (8 mg/m2/day), the dose-limiting toxicity of this agent is myelosuppression. The RPTD for further testing of this schedule is 6 mg/m2 daily x 5 days.
| Year | Citations | |
|---|---|---|
Page 1
Page 1